Spinocerebellar ataxia type 7 in South Africa: Epidemiology, pathogenesis and therapy by Watson, L et al.
S107     June 2016, Vol. 106, No. 6 (Suppl 1)
THE NEW MILLENNIUM
Inherited neurodegenerative diseases, characterised by progressive 
symptoms and a lengthy disease course, present a significant economic 
and psychological burden to affected families. The Department (now 
Division) of Human Genetics at the University of Cape Town (UCT) 
has a long history of research into these conditions, beginning under 
the leadership of Prof. Peter Beighton in 1972. This research has 
focused primarily on the polyglutamine (polyQ) diseases, a subset of 
monogenic neurodegenerative diseases with a well-defined genetic 
aetiology, which includes Huntington’s disease (HD) and six of the 
spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17).[1] Complementing 
the work done in the research laboratories, an internationally accepted 
counselling and testing protocol for these conditions has been offered 
by the Division’s clinical service, and latterly, in conjunction with the 
National Health Laboratory Service (NHLS), since 1995.[2]
Seminal work by Michael Hayden, under Beighton’s mentorship, 
provided the first comprehensive survey of HD in South Africa (SA) 
in 1979.[3] This laid the foundation for a number of MSc and PhD 
projects exploring the molecular basis of HD, including that of Jacquie 
Greenberg, herself now Professor of Human Genetics at UCT. In 
2013, UCT researchers, in collaboration with Hayden (now University 
Killam Professor at the Department of Medical Genetics, University 
of British Columbia) and others, identified novel, ethnically distinct 
haplotypes among SA HD patients, providing the first evidence for 
multiple origins of the disease-causing mutation within the black SA 
population.[4] These findings are likely to have significant implications 
for future therapies.[5] (The history of HD research in Africa is reviewed 
elsewhere in this issue by Baine et al.)
Research into the polyQ SCAs at UCT was initiated by Alan 
Bryer, who completed his PhD on ‘The Inherited Ataxias in SA’ 
in 1994. Subsequent work, by Bryer and others, traced the origin 
and epidemiology of the polyQ SCA mutations in SA, identifying 
founder effects in two of the SCAs (SCA1 and 7), which may 
extend to neighbouring countries.[6-9] SCA7, in particular, has 
been the focus of concerted local research efforts over the past 
10 years. The unusually high frequency of this condition in the SA 
population, coupled with unique phenotypic characteristics, make 
it an attractive prospect for therapeutic development. Research into 
the disease has since progressed from early molecular genetics-
based investigations to the development of cutting-edge stem 
cell models and gene-silencing therapies, in an effort to better 
understand and treat the disease.
Spinocerebellar ataxia type 7 
The inherited polyQ diseases all arise from a common type of 
mutation – an expanded trinucleotide CAG repeat tract within the 
coding region of the disease-causing gene, which is translated into an 
abnormally long polyglutamine tract in the mutant protein.[10] Although 
heterogeneous, a number of common pathogenic mechanisms have 
been proposed to account for polyQ protein toxicity, including 
proteolytic cleavage (leading to the production of toxic fragments), 
impairment of the ubiquitin-proteasome pathway, aggregation of 
the mutant protein (involving the sequestration of wild-type polyQ 
protein and other important cellular components), dysregulation of 
transcription, and mitochondrial dysfunction.[1]
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Disorders of the nervous system represent a significant proportion of the global burden of non-communicable diseases, due to the trend 
towards ageing populations. The Department (now Division) of Human Genetics at the University of Cape Town (UCT) has been involved 
in pioneering research into these diseases since the appointment of Prof. Peter Beighton as Head of Department in 1972. Beighton’s emphasis 
on understanding the genetic basis of disease laid the groundwork for investigations into several monogenic neurodegenerative conditions, 
including Huntington’s disease and the polyglutamine spinocerebellar ataxias (SCAs). In particular, SCA7, which occurs at an unusually 
high frequency in the South African (SA) population, was identified as a target for further research and therapeutic development. Beginning 
with early epidemiological surveys, the SCA7 project progressed to molecular genetics-based investigations, leading to the identification of 
a founder effect in the SA SCA7 patient population in the mid-2000s. Capitalising on the founder haplotype shared by many SCA7 patients, 
UCT researchers went on to develop the first population-specific gene-silencing approach for the disease. More recently, efforts have shifted 
to the development of a more accurate model to decipher the precise mechanisms of neurodegeneration, using induced pluripotent stem 
cells derived from SA SCA7 patients. In many ways, the SA SCA7 journey reflects the legacy and vision of Prof. Peter Beighton, and his 
efforts to establish world-class, collaborative research into diseases affecting the African continent.
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SCA7 is a dominantly inherited polyQ disease, caused by a CAG 
repeat expansion within the ATXN7 gene. Normal ATXN7 alleles 
typically contain between 4 and 35 CAG repeats, while pathological 
alleles range in length from 36 to over 400 repeats.[11] Intermediate 
alleles in the 28 - 35 CAG repeat range may undergo further 
expansion into the pathogenic range during vertical transmission 
(particularly in the case of paternal transmission), resulting in the 
appearance of disease in the offspring of asymptomatic carriers.[12]
Clinically, SCA7 is characterised by cerebellar ataxia, dysarthria, 
dysphagia and exaggerated deep tendon reflexes.[13] It is distinct 
from other polyQ diseases by virtue of the presence of progressive 
macular degeneration, which results in severe visual impairment, 
in addition to the gait and speech difficulties characteristic of 
cerebellar degeneration.[14] The neuropathology of SCA7 shows a 
strong correlation with disease phenotype. Within the cerebellum, 
SCA7 patients typically exhibit extensive loss of Purkinje cells, with 
only minimal alterations to the cerebellar granule layer.[15] The retinal 
phenotype results primarily from the dysfunction of the cone, and later, 
rod photoreceptors, hence its classification as a cone-rod dystrophy.[16]
Wildtype ATXN7 protein is ubiquitously expressed, and has been 
shown to play an important role in transcriptional regulation, as 
a component of several transcriptional co-activator complexes.[17] 
Mutations in ATXN7 have been shown to inhibit the histone 
acetylation function of these complexes, leading to transcriptional 
dysregulation, even before the onset of disease symptoms.[18,19] 
However, the precise mechanism by which mutations in this gene 
cause specific degeneration of the cerebellum and retina remains 
incompletely understood.
A uniquely South African therapy?
SCA7 is one of the rarer polyQ disorders, with a prevalence of less 
than 1 per 100 000 worldwide.[10] In SA, however, SCA7 is the second 
most prevalent dominantly inherited ataxia, after SCA1.[20] This 
unusual pattern was first described by Bryer and colleagues[8] at UCT, 
who reported an increased prevalence of SCA7 in the SA population, 
compared with the rest of the world (then 22.2% of total dominant 
ataxia cases, compared with a frequency of less than 5% elsewhere). 
A follow-up survey by UCT researchers in 2012 reported a similar 
trend, with SCA7 now accounting for 26.6% of polyQ ataxia cases.[20] 
(An updated review of the unique epidemiology of the SA SCAs is 
provided elsewhere in this issue, by Smith et al.)
SCA7 occurs almost exclusively in individuals of black African 
origin, hypothesised to be the result of a founder event[7] similar 
to those proposed for coloured and white SCA1 patients in SA.[9] 
SA SCA7 patients are thus presumed to have descended from 
a common ancestor, and should consequently share a common 
haplotype surrounding ATXN7, including alleles of common single 
nucleotide polymorphisms (SNPs) within the region. Indeed, the 
observation that over 50% of SA SCA7 patients are heterozygous for 
a common SNP (rs3774729) in the 3’ region of ATXN7, such that 
the A and G alleles of the SNP are associated with the mutant and 
wildtype transcripts, respectively, has provided the foundation for 
the development of RNA interference (RNAi)-based therapy for this 
patient population.[7,21]
In 2009, researchers at the UCT Division of Human Genetics, 
together with collaborators at the Universities of Oxford and the 
Witwatersrand, published the first evidence for an effective allele-
specific RNAi-based therapy for SCA7.[21] Multiple short hairpin 
RNAs (shRNAs) were screened, in order to identify sequences 
capable of selectively targeting the ATXN7-linked SNP. Incorporating 
a single nucleotide mismatch to the wildtype RNA target sequence 
at position 16 from the 5’ end of the active shRNA guide sequence 
was shown to confer maximal mutation selectivity in a heterozygous 
model, in which HEK293 cells were cotransfected with mutant 
and wildtype full-length ATXN7. Treatment with the allele-specific 
shRNA resulted in efficient knockdown of the mutant ATXN7 
transcript to 7% of control levels (p=0.05) with minimal effects on the 
wildtype allele, and led to a marked reduction in ATXN7 aggregation. 
A similar trend was observed when the allele-specific guide sequence 
was incorporated into a microRNA (miRNA) mimic. 
Although significant, this study was nonetheless hindered by its 
use of an artificially heterozygous system, reliant on overexpression of 
exogenous ATXN7 alleles. To evaluate therapeutic efficacy in a more 
genetically accurate disease model, this work was followed up by a 
2014 study, using cultured fibroblasts from SCA7 patients.[22] The same 
RNAi effectors were shown to discriminate between endogenous 
wildtype and mutant alleles, using a novel qPCR assay, with primers 
capable of discriminating between alleles of the disease-linked SNP. 
Selective silencing of mutant ATXN7 was also demonstrated to 
ameliorate a mild transcriptional phenotype in these cells. Consistent 
with previously described SCA7 models, a twofold increase in the 
heat shock protein gene DNAJA1 and a twofold decrease in the 
de-ubiquitinating enzyme UCHL1 were observed in SCA7 patient 
fibroblasts at the transcriptional level, relative to control lines. 
Sustained knockdown of mutant ATXN7 resulted in restoration 
of both transcripts towards normal levels, suggesting that patient 
fibroblasts may serve as useful models for evaluating both dosage and 
efficacy of new therapies.
Disease modelling using induced 
pluripotent stem cells
Despite these promising results, however, concerns remain 
regarding the utility of non-central nervous system (CNS) tissues 
for modelling complex neurodegenerative diseases. Indeed, the 
lack of suitable disease models remains a major barrier to the 
study of these conditions. Although several SCA7 mouse models 
have been generated, none of these successfully recapitulate all 
facets of the disease.[23] This is largely due to challenges inherent in 
modelling neurodegeneration in mice, including delayed onset of 
symptoms, slow disease progression, and species-specific differences 
in physiology.
Recently developed induced pluripotent stem cell (iPSC) 
technology offers the opportunity to generate stem cells from 
somatic cells, through the exogenous expression of stem cell-specific 
transcription factors (so-called ‘reprogramming factors’) OCT3/4, 
SOX2, c-MYC and KLF4.[24] The resultant stem cells can then be 
differentiated into any cell type of the body, allowing the study of 
disease-relevant CNS tissues without the need for invasive surgical 
techniques.
As part of an ongoing collaboration between researchers at the 
University of Oxford and UCT, our research group has pioneered 
the use of iPSCs to study SCA7, generating the first iPSCs from 
SA SCA7 patients in 2012.[25] These cells have subsequently 
been differentiated into neurons and retinal cells,[25,26] and used 
to identify transcriptional and electrophysiological aberrations, 
which may be linked to the presence of mutant ATXN7. These 
results provide important preliminary evidence of a disease 
phenotype in SCA7 iPSC-derived cells, establishing a valuable 
model for the study of neurodegenerative disease. A number of 
challenges remain to be addressed, however. Chief among these 
is the differentiation of iPSCs into cerebellar-specific neurons, 
in order to generate more accurate models of the disease – a task 
made particularly difficult by the complex molecular mechanisms 
underpinning cerebellar development.[27] Future work will seek to 
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further develop these cells as a resource for the development of 
population-specific therapies.
SA SCA7 patient cells also played a key role in a breakthrough 
publication in 2014, in which a large collaboration headed by 
researchers at the University of Oxford identified a role for long 
non-coding RNAs in directing the tissue specificity of SCA7 
pathogenesis.[28] Based on the observed correlation between 
expression of ATXN7 and a conserved retropseudogene, lnc-SCA7, 
in human and mouse CNS, Tan and colleagues[28] proposed a 
regulatory loop, in which STAGA is required for the transcription 
initiation of miR-124, the most abundantly expressed miRNA in the 
CNS. This miRNA in turn mediates the post-transcriptional cross-
talk between lnc-SCA7 and ATXN7, which is itself a component of 
STAGA. SCA7 patient fibroblasts were used to validate the hypothesis 
that mutations in ATXN7 may disrupt these regulatory interactions, 
leading to a neuron-specific increase in ATXN7 expression, thereby 
contributing to the selective neurodegeneration observed in SCA7.
Conclusion and perspectives
The SA SCA7 story spans nearly two decades, combining the 
expertise of a large number of clinical and basic science researchers. 
Beginning with descriptive molecular genetics investigations, the 
project has expanded to incorporate cutting-edge stem cell and gene-
silencing technologies. In many ways, this reflects the leadership of 
Prof. Peter Beighton, and his vision for a world-class Human Genetics 
Department at UCT, capable of fostering collaborative research of 
the highest quality. As mentor to several of the senior scientists who 
would go on to pioneer SCA7 research in SA, Prof. Beighton laid the 
foundation for the current generation of neurogenetics researchers. 
Current work on SCA7 is thus a reflection of his legacy, unravelling 
the complexities of SCA7 pathogenesis and developing patient-
specific therapies.
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